Table II.
Association between the CIMP and the clinicopathological features of 104 colorectal cancers.
| Features | Total | CIMP-N | CIMP-L | CIMP-H | P-valuea |
|---|---|---|---|---|---|
| No. of patients | 104 (100.0) | 9 (8.7) | 76 (73.1) | 19 (18.3) | |
| Mean age, years | 63.4 | 60.7 | 62.9 | 66.6 | 0.317 |
| Gender, n (%) | |||||
| Male | 51 (49.0) | 5 (55.6) | 35 (46.1) | 10 (52.6) | |
| Female | 53 (51.0) | 4 (44.4) | 41 (53.8) | 9 (47.4) | 0.471 |
| Tumor location, n (%) | |||||
| Proximal | 42 (40.4) | 1 (11.1) | 32 (42.1) | 9 (47.4) | |
| Distal | 62 (59.6) | 8 (88.9) | 44 (57.9) | 10 (52.6) | 0.118 |
| Mean tumour size, mm | 48.2 | 47.7 | 49.7 | 43.7 | 0.466 |
| Histology, n (%) | |||||
| Differentiated | 90 (86.5) | 7 (77.8) | 67 (91.3) | 16 (84.2) | |
| Undifferentiated | 14 (13.5) | 2 (22.2) | 9 (8.7) | 3 (15.8) | 0.680 |
| Lymphatic invasion, n (%) | |||||
| Negative | 51 (49.0) | 5 (55.6) | 38 (50.0) | 8 (42.1) | |
| Positive | 53 (51.0) | 4 (44.4) | 38 (50.0) | 11 (58.9) | 0.760 |
| Venous invasion, n (%) | |||||
| Negative | 66 (57.4) | 5 (55.6) | 47 (60.3) | 14 (73.7) | |
| Positive | 38 (42.6) | 4 (44.4) | 29 (39.7) | 5 (26.3) | 0.543 |
| Tumor stage, n (%) | |||||
| 0 | 2 (1.9) | 0 (0.0) | 2 (2.6) | 0 (0.0) | |
| I | 16 (15.4) | 1 (11.1) | 12 (15.8) | 3 (15.8) | |
| II | 32 (30.8) | 3 (33.3) | 21 (20.2) | 8 (42.1) | |
| III | 39 (37.5) | 1 (11.1) | 33 (43.4) | 5 (26.3) | |
| IV | 15 (14.4) | 4 (44.4) | 8 (10.5) | 3 (15.8) | 0.227 |
| Distant metastases at diagnosis, n (%) | |||||
| Negative | 89 (85.6) | 5 (55.6) | 68 (89.5) | 16 (84.2) | |
| Positive | 15 (14.4) | 4 (44.4) | 8 (10.5) | 3 (15.8) | 0.023 |
| Postoperative chemotherapy, n (%) | |||||
| No | 35 (33.7) | 2 (22.2) | 26 (34.2) | 7 (36.8) | |
| Yes | 69 (66.3) | 7 (77.8) | 50 (65.8) | 12 (63.2) | 0.719 |
| Tumor recurrenceb, n (%) | |||||
| Negative | 64 (71.9) | 3 (60.0) | 46 (61.6) | 15 (93.7) | |
| Positive | 25 (28.1) | 2 (40.0) | 22 (32.4) | 1 (6.3) | 0.093 |
| MLH1 methylation, n (%) | |||||
| − | 94 (90.4) | 9 (100.0) | 72 (94.7) | 13(68.4) | |
| + | 10 (9.6) | 0 (0.0) | 4 (5.3) | 6 (31.6) | 0.005 |
a
Assessed by analysis of variance or Kruskal-Wallis test.
b
Stage 0-III tumors.
CIMP, CpG island methylator phenotype; CIMP-L, CIMP-low; CIMP-H, CIMP-high; CIMP-N, CIMP-negative, MLH1, MutL homolog 1; NS, not significant.